Cervical Cancer News and Research RSS Feed - Cervical Cancer News and Research

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.
HPV vaccination may be beneficial for CKD patients but not for kidney transplant recipients

HPV vaccination may be beneficial for CKD patients but not for kidney transplant recipients

Human papillomavirus (HPV) vaccination stimulates robust and sustained immune responses in girls and young women with chronic kidney disease (CKD) and those on dialysis, but less optimal responses to the vaccine were observed among those with a kidney transplant. [More]
MedUni Vienna researchers develop new treatment for pre-stages of cervical cancer

MedUni Vienna researchers develop new treatment for pre-stages of cervical cancer

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have developed a new treatment for the pre-stages of cervical cancer, caused by human papilloma virus (HPV) infection. [More]
Study shows free gynecological pap test screening did not increase women participation

Study shows free gynecological pap test screening did not increase women participation

1,562 women were offered free gynecological pap test screening in three socioeconomically disadvantaged areas in Gothenburg, in 2013. A new study from Sahlgrenska Academy, Närhälsan and the Regional Cancer Center West now shows that these women did not participate to a greater degree than the group that was offered the screening for the usual fee. [More]
Unlocking intrinsically disordered proteins: an interview with Peter Wright

Unlocking intrinsically disordered proteins: an interview with Peter Wright

I'm a professor in the Department of Integrative Structural and Computational Biology at The Scripps Research Institute. I have been performing NMR research on proteins for nearly 40 years. [More]
Cancer patients who miss scheduled radiation therapy appointments have worse outcomes

Cancer patients who miss scheduled radiation therapy appointments have worse outcomes

Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine's NCI-designated Albert Einstein Cancer Center have found. [More]
Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. [More]
Using centrifugal elutriation and flow cytometry to answer biological questions: an interview with Peter Lopez

Using centrifugal elutriation and flow cytometry to answer biological questions: an interview with Peter Lopez

Flow Cytometry, the measurement of various cellular characteristics as they flow through a measuring apparatus, has so many applications that it's hard to know where to begin. [More]
Spotting the symptoms of cervical cancer

Spotting the symptoms of cervical cancer

Every year, around 3,000 women in the UK are diagnosed with cervical cancer. Whilst rare, cervical cancer can be a life-changing and dangerous disease. [More]
New report reveals striking variation in cancer burden within AANHPI population

New report reveals striking variation in cancer burden within AANHPI population

A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors. [More]
UTHealth receives nearly $5.7 million from CPRIT for cancer research

UTHealth receives nearly $5.7 million from CPRIT for cancer research

The Cancer Prevention & Research Institute of Texas has awarded nearly $5.7 million in grants to The University of Texas Health Science Center at Houston School of Public Health. The grants will fund projects that train innovative cancer researchers, increase breast and cervical cancer screening among Hispanics and raise awareness about the human papillomavirus (HPV) vaccine. [More]
CMFT adopts ZedScan system to improve cervical cancer care

CMFT adopts ZedScan system to improve cervical cancer care

DP Medical Systems Ltd has secured a deal with Central Manchester University Hospitals NHS Foundation Trust (CMFT) to adopt ZedScan™ as part of its cervical cancer care pathway. [More]
Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen Pharmaceuticals, Inc. announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen's own AdVac® technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer. [More]
Discovery could pave way for targeted therapies to treat penile cancer

Discovery could pave way for targeted therapies to treat penile cancer

Researchers have identified potential genetic alterations in penile cancer that could pave the way for targeted treatments. [More]
New combination approach to eradicate established tumors

New combination approach to eradicate established tumors

A laboratory study conducted at Leiden University Medical Center in the Netherlands has found that immunotherapy can be efficiently combined with photodynamic therapy (PDT) to eradicate established tumors. The approach results in strong local tumor destruction and a robust systemic immune response against the disease. [More]
European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a detailed scientific review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines. [More]
Research sheds new light on the fight against tonsil cancer

Research sheds new light on the fight against tonsil cancer

Researchers at Simon Fraser University and the BC Cancer Agency have developed a groundbreaking method to identify and separate stem cells that reside in the tonsils. Their research, which sheds new light on the fight against oral cancer, is published today in the journal Stem Cell Reports. [More]
Around 20% of ethnic school girls not vaccinated against HPV

Around 20% of ethnic school girls not vaccinated against HPV

Around 20 per cent of girls from ethnic minority backgrounds are not being vaccinated against the Human Papilloma Virus (HPV) because they feel they don't need to have it, according to a Cancer Research UK survey presented today at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool*. [More]
UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

Cervical cancer is the fourth most frequently occurring cancer in women. Human papillomavirus (HPV) is present in 99 percent of cervical cancers and is considered to be their cause. While most HPV infections will clear naturally within a few years, there has been no treatment available to hasten or improve the chance of natural eradication. [More]
First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections. [More]
Outreach program increases completion of HPV vaccination series by teens in safety-net settings

Outreach program increases completion of HPV vaccination series by teens in safety-net settings

A joint study by UT Southwestern Medical Center and Parkland Health & Hospital System investigators found that a multicomponent outreach program increased completion of the three-dose human papillomavirus (HPV) vaccination series that reduces the risk of cervical cancer caused by the virus. [More]
Advertisement
Advertisement